Precision Therapeutics for Women's Health
Developing precision RNA therapeutics for women’s health.
Esma Bio is a preclinical-stage biotechnology company developing targeted RNA therapeutics for chronic women’s health conditions. Our lead endometriosis program aims to act within lesions, with the goal of developing a treatment that does not rely on systemic hormonal suppression.
Our programs are preclinical. Safety and efficacy have not been established in humans.
190M
estimated reproductive-age women affected worldwide
4–12 years
reported average time to diagnosis
Recurrence
symptoms can return after treatment
Source: World Health Organization, 2025. Diagnostic-delay estimates vary by setting.
The Unmet Need
Endometriosis needs more treatment options.
Endometriosis affects an estimated 190 million reproductive-age women worldwide. Persistent symptoms, delayed diagnosis, and recurrence after treatment create a substantial need for additional treatment options.
190M
estimated reproductive-age women affected worldwide
4–12 years
reported average time to diagnosis
Recurrence
symptoms can return after treatment
Source: World Health Organization, 2025. Diagnostic-delay estimates vary by setting.
Disease Burden
A substantial burden on daily life
Endometriosis can cause chronic pelvic pain and infertility and can disrupt work, education, relationships, and daily life. Symptoms and their impact vary widely between individuals.
Treatment Limitations
Effective treatments, persistent unmet needs
Medicines and surgery can provide meaningful relief, but treatment response and tolerability vary. Some hormonal treatments carry bone-density risks and limits on treatment duration. Surgery can remove lesions, yet symptoms or lesions may recur. Additional treatment options are needed.
The Esma Bio Approach
Investigating targeted RNA therapeutics for endometriosis.
Our preclinical research focuses on RNA therapeutics intended to act within endometriotic lesions. We aim to address disease-associated processes without relying on systemic hormonal suppression. Lesion selectivity, therapeutic benefit, and effects on normal tissues and endocrine function remain to be established.
Development Roadmap
Our research pipeline.
Our pipeline focuses on endometriosis, with additional discovery programs in women’s cancers and androgenetic alopecia, commonly known as pattern hair loss. All programs are preclinical.
Additional program information may be shared with prospective partners under an appropriate confidentiality agreement.
